MLTXMoonLake Immunotherapeutics
Is it safe?
Caution warranted: heavy debt (BB) and big price swings.
Insiders were net sellers (-$3.6M, 90 days to Oct 8, 2026), selling is often routine.
Net cash, but unprofitable, speculative. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -90% · now 83% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can MLTX take a bad year?
MoonLake Immunotherapeutics holds $438M more cash than debt, and is burning $56M a quarter, about 2.4 years of cover.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Cash runway
- 2.4 years
Cash runway · burning $56M a quarter at the current rate
- Annualised volatility
- 91%
Annualised volatility · three times the market's own swing
Details›
- Total debtQ2 2026
- $100M
- Cash and short-term investments
- $537M
- Net cash
- $438M
- EBITDA, trailing twelve months
- −$265M
- Operating profit, trailing twelve months
- −$268M
- Debt / equity
- 0.23×
- Annualised volatilitytwo years of daily moves
- 91%
- Worst drawdown on file
- −90%
- Below its 52-week high
- 83%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.